Global Necrotising Enterocolitis Market Growth (Status and Outlook) 2023-2029

Global Necrotising Enterocolitis Market Growth (Status and Outlook) 2023-2029

Necrotizing enterocolitis (NEC) is a devastating disease that affects mostly the intestine of premature infants. The wall of the intestine is invaded by bacteria, which cause local infection and inflammation that can ultimately destroy the wall of the bowel (intestine). Such bowel wall destruction can lead to perforation of the intestine and spillage of stool into the infant’s abdomen, which can result in an overwhelming infection and death.

LPI (LP Information)' newest research report, the “Necrotising Enterocolitis Industry Forecast” looks at past sales and reviews total world Necrotising Enterocolitis sales in 2022, providing a comprehensive analysis by region and market sector of projected Necrotising Enterocolitis sales for 2023 through 2029. With Necrotising Enterocolitis sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Necrotising Enterocolitis industry.

This Insight Report provides a comprehensive analysis of the global Necrotising Enterocolitis landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Necrotising Enterocolitis portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Necrotising Enterocolitis market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Necrotising Enterocolitis and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Necrotising Enterocolitis.

The global Necrotising Enterocolitis market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

Treatment of Necrotising Enterocolitis consists primarily of supportive care including providing bowel rest by stopping enteral feeds, gastric decompression with intermittent suction, fluid repletion to correct electrolyte abnormalities and third-space losses, support for blood pressure, parenteral nutrition, and prompt antibiotic therapy.

This report presents a comprehensive overview, market shares, and growth opportunities of Necrotising Enterocolitis market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Stage I
Stage II
Stage III

Segmentation by application
Hospital & Clinic
Diagnostic Center

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
GlaxoSmithKline
Pfizer
Eli Lilly And Company
Bayer HealthCare
Becton, Dickinson And Company
Bristol-Myers Squibb Company
Medtronic

Please note: The report will take approximately 2 business days to prepare and deliver.